Xenograft, Orthotopic, Leukemia, MV-4-11

  1. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
The MV-4-11 human biphenotypic B myelomonocytic leukemia xenograft disseminated disease model is used to evaluate therapeutic efficacy of investigational antineoplastic agent(s) in immune compromised mice.
ORGANISM
Mouse
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Specific-pathogen-free (SPF) female NOD/SCID mice bred in an animal isolator (IVC racks) under SPF conditions at 22 ± 2°C are used. Viable human leukemic MV-4-11 (AML M5) cells, at 1 x 10⁷ cells per mouse, are injected intravenously into the tail vein of experimental mice. A single dose of cyclophosphamide (150 mg/kg) is administered intraperitoneally (IP) 3 days prior to tumor cell implantation. Dose administrations are initiated on the day of tumor cell implantation (denoted as Day 1) at 2 h post-implantation. Mortality is recorded daily during the study period. Body weights are measured and recorded twice weekly. Prevention of mortality is recorded in percentage and the significance is assessed by Fisher’s exact test. Study will continue for 8 weeks. Percent Median Time of Survival (%MTS) is expressed as the percentage by which the treated group median time of survival is delayed in reaching the established survival endpoint compared to the controls using the formula ((T-C)/C)) x 100 where T and C are median times (days) to reach the survival endpoint for the treated and control group, respectively.
CRITERIA FOR SIGNIFICANCE
≥ 50% of survival
TURNAROUND TIME
STANDARD
50 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Oncology/Immuno-Oncology
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences